|
|
Rheumatoid Arthritis Drug Discoveries: What the Future HoldsPublished by: Espicom Healthcare Intelligence Published: Mar. 18, 2008 - 250 Pages Table of Contents
AbstractOver 200 pages of product analysis, forecasts and data.Providing… Detailed assessment and 5-year forecasts for current leading products by value A detailed review and assessment of up and coming products Unique product assessment and scoring Major approaches Adenosine receptor antagonist B-cell targeted therapy Cathepsin-S inhibitors Chemokine receptor antagonists DHODH inhibitors Glucocorticoids Interleukin inhibitors Kinase inhibitors Lymphotoxin beta and light pathway inhibitor Non-steroidal anti-inflammatory drugs RANK ligand inhibitor T-cell co-stimulation modulator TNF inhibitors Traditional disease-modifying anti-rheumatic drugs The rheumatoid arthritis sector is set for substantial growth. With significant unmet clinical need and the progressive introduction of higher value and effective biopharmaceuticals, the market is expected to more than double in value to US$27 billion by 2015. The value of the rheumatoid arthritis (RA) market currently stands at approximately US$11.6 billion and is continuing to grow, driven mainly by the biologic DMARDs. It is dominated by five major pharma companies: Abbott, Amgen, Johnson & Johnson, Schering-Plough and Wyeth, which between them market three of the most successful biologics, the tumour necrosis factor inhibitors Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab). Research into new treatments is intense, driven by the need for safer and even more effective medications with more convenient dosing schedules. GlaxoSmithKline, Johnson & Johnson, Roche, Schering-Plough and UCB all have biologics in the late phases of development, while Pfizer is pinning its hopes on its oral kinase inhibitors, which are currently in Phase II development. As these new therapies come on board and the market becomes more competitive, the prospects for RA patients can only improve. This report provides a complete assessment of the market’s potential This new management report provides a complete examination of the RA market and its prospects in the medium term. Packed with analysis and forecasts, anyone needing to understand the drivers of this fast growing sector need look no further. Despite falling prevalence levels in the future in developed markets, there still remains significant unmet need, with many patients both undiagnosed and untreated. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||